The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies.
K. P. Papadopoulos
Research Funding - Regeneron
N. G. Chau
No relevant relationships to disclose
A. Patnaik
Research Funding - Regeneron
L. Adriaens
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
A. S. Lalani
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
C. Daly
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
L. L. Siu
Research Funding - Regeneron